Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Dec;71(12):9206–9213. doi: 10.1128/jvi.71.12.9206-9213.1997

Activation of transgene expression by early region 4 is responsible for a high level of persistent transgene expression from adenovirus vectors in vivo.

D E Brough 1, C Hsu 1, V A Kulesa 1, G M Lee 1, L J Cantolupo 1, A Lizonova 1, I Kovesdi 1
PMCID: PMC230223  PMID: 9371579

Abstract

The persistence of transgene expression has become a hallmark for adenovirus vector evaluation in vivo. Although not all therapeutic benefit in gene therapy is reliant on long-term transgene expression, it is assumed that the treatment of chronic diseases will require significant persistence of expression. To understand the mechanisms involved in transgene persistence, a number of adenovirus vectors were evaluated in vivo in different strains of mice. Interestingly, the rate of vector genome clearance was not altered by the complete deletion of early region 4 (E4) in our vectors. The GV11 (E1- E4-) vector genome cleared with a similar kinetic profile as the GV10 (E1-) vector genome in immunocompetent and immunocompromised mice. These results suggest that the majority of adenovirus vector genomes are eliminated from transduced tissue via a mechanism(s) independent of T-cell, B-cell, and NK cell immune mechanisms. While the levels of persistence of transgene expression in liver or lung transduced with GV10 and GV11 vectors expressing beta-galactosidase, cystic fibrosis transmembrane conductance regulator, or secretory alkaline phosphatase were similar in immunocompetent mice, a marked difference was observed in immunocompromised animals. Levels of transgene expression initially from both GV10 and GV11 vectors were the same. However, GV11 transgene expression correlated with loss of vector genome, while GV10 transgene expression persisted at a high level. Coadministration and readministration of GV10 vectors showed that E4 provided in trans could activate transgene expression from the GV11 vector genome. While transgene expression activity per genome from the GV10 vector is clearly activated, expression from a cytomegalovirus promoter expression cassette in a GV11 vector appeared to be further inactivated as a function of time. Understanding the molecular mechanisms underlying these expression effects will be important for developing persistent adenovirus vectors for chronic applications.

Full Text

The Full Text of this article is available as a PDF (966.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Armentano D., Zabner J., Sacks C., Sookdeo C. C., Smith M. P., St George J. A., Wadsworth S. C., Smith A. E., Gregory R. J. Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J Virol. 1997 Mar;71(3):2408–2416. doi: 10.1128/jvi.71.3.2408-2416.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barr D., Tubb J., Ferguson D., Scaria A., Lieber A., Wilson C., Perkins J., Kay M. A. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Ther. 1995 Mar;2(2):151–155. [PubMed] [Google Scholar]
  3. Berger J., Hauber J., Hauber R., Geiger R., Cullen B. R. Secreted placental alkaline phosphatase: a powerful new quantitative indicator of gene expression in eukaryotic cells. Gene. 1988 Jun 15;66(1):1–10. doi: 10.1016/0378-1119(88)90219-3. [DOI] [PubMed] [Google Scholar]
  4. Brough D. E., Lizonova A., Hsu C., Kulesa V. A., Kovesdi I. A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4. J Virol. 1996 Sep;70(9):6497–6501. doi: 10.1128/jvi.70.9.6497-6501.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bruder J. T., Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol. 1997 Jan;71(1):398–404. doi: 10.1128/jvi.71.1.398-404.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Carvalho T., Seeler J. S., Ohman K., Jordan P., Pettersson U., Akusjärvi G., Carmo-Fonseca M., Dejean A. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J Cell Biol. 1995 Oct;131(1):45–56. doi: 10.1083/jcb.131.1.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chen H. H., Mack L. M., Kelly R., Ontell M., Kochanek S., Clemens P. R. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1645–1650. doi: 10.1073/pnas.94.5.1645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Crystal R. G. Transfer of genes to humans: early lessons and obstacles to success. Science. 1995 Oct 20;270(5235):404–410. doi: 10.1126/science.270.5235.404. [DOI] [PubMed] [Google Scholar]
  9. Dai Y., Schwarz E. M., Gu D., Zhang W. W., Sarvetnick N., Verma I. M. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1401–1405. doi: 10.1073/pnas.92.5.1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Dedieu J. F., Vigne E., Torrent C., Jullien C., Mahfouz I., Caillaud J. M., Aubailly N., Orsini C., Guillaume J. M., Opolon P. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol. 1997 Jun;71(6):4626–4637. doi: 10.1128/jvi.71.6.4626-4637.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dobner T., Horikoshi N., Rubenwolf S., Shenk T. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. Science. 1996 Jun 7;272(5267):1470–1473. doi: 10.1126/science.272.5267.1470. [DOI] [PubMed] [Google Scholar]
  12. Doucas V., Ishov A. M., Romo A., Juguilon H., Weitzman M. D., Evans R. M., Maul G. G. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 1996 Jan 15;10(2):196–207. doi: 10.1101/gad.10.2.196. [DOI] [PubMed] [Google Scholar]
  13. Engelhardt J. F., Litzky L., Wilson J. M. Prolonged transgene expression in cotton rat lung with recombinant adenoviruses defective in E2a. Hum Gene Ther. 1994 Oct;5(10):1217–1229. doi: 10.1089/hum.1994.5.10-1217. [DOI] [PubMed] [Google Scholar]
  14. Engelhardt J. F., Ye X., Doranz B., Wilson J. M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci U S A. 1994 Jun 21;91(13):6196–6200. doi: 10.1073/pnas.91.13.6196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Fang B., Wang H., Gordon G., Bellinger D. A., Read M. S., Brinkhous K. M., Woo S. L., Eisensmith R. C. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 1996 Mar;3(3):217–222. [PubMed] [Google Scholar]
  16. Gao G. P., Yang Y., Wilson J. M. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol. 1996 Dec;70(12):8934–8943. doi: 10.1128/jvi.70.12.8934-8943.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Goodrum F. D., Shenk T., Ornelles D. A. Adenovirus early region 4 34-kilodalton protein directs the nuclear localization of the early region 1B 55-kilodalton protein in primate cells. J Virol. 1996 Sep;70(9):6323–6335. doi: 10.1128/jvi.70.9.6323-6335.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Guidotti L. G., Chisari F. V. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol. 1996 Aug;8(4):478–483. doi: 10.1016/s0952-7915(96)80034-3. [DOI] [PubMed] [Google Scholar]
  19. Javier R. T. Adenovirus type 9 E4 open reading frame 1 encodes a transforming protein required for the production of mammary tumors in rats. J Virol. 1994 Jun;68(6):3917–3924. doi: 10.1128/jvi.68.6.3917-3924.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Javier R., Raska K., Jr, Macdonald G. J., Shenk T. Human adenovirus type 9-induced rat mammary tumors. J Virol. 1991 Jun;65(6):3192–3202. doi: 10.1128/jvi.65.6.3192-3202.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Javier R., Raska K., Jr, Shenk T. Requirement for the adenovirus type 9 E4 region in production of mammary tumors. Science. 1992 Aug 28;257(5074):1267–1271. doi: 10.1126/science.1519063. [DOI] [PubMed] [Google Scholar]
  22. Javier R., Shenk T. Mammary tumors induced by human adenovirus type 9: a role for the viral early region 4 gene. Breast Cancer Res Treat. 1996;39(1):57–67. doi: 10.1007/BF01806078. [DOI] [PubMed] [Google Scholar]
  23. Jooss K., Yang Y., Wilson J. M. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther. 1996 Aug 20;7(13):1555–1566. doi: 10.1089/hum.1996.7.13-1555. [DOI] [PubMed] [Google Scholar]
  24. Kaplan J. M., Armentano D., Sparer T. E., Wynn S. G., Peterson P. A., Wadsworth S. C., Couture K. K., Pennington S. E., St George J. A., Gooding L. R. Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum Gene Ther. 1997 Jan 1;8(1):45–56. doi: 10.1089/hum.1997.8.1-45. [DOI] [PubMed] [Google Scholar]
  25. Kass-Eisler A., Falck-Pedersen E., Elfenbein D. H., Alvira M., Buttrick P. M., Leinwand L. A. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther. 1994 Nov;1(6):395–402. [PubMed] [Google Scholar]
  26. Kay M. A., Holterman A. X., Meuse L., Gown A., Ochs H. D., Linsley P. S., Wilson C. B. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nat Genet. 1995 Oct;11(2):191–197. doi: 10.1038/ng1095-191. [DOI] [PubMed] [Google Scholar]
  27. Kay M. A., Meuse L., Gown A. M., Linsley P., Hollenbaugh D., Aruffo A., Ochs H. D., Wilson C. B. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4686–4691. doi: 10.1073/pnas.94.9.4686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kleinberger T., Shenk T. Adenovirus E4orf4 protein binds to protein phosphatase 2A, and the complex down regulates E1A-enhanced junB transcription. J Virol. 1993 Dec;67(12):7556–7560. doi: 10.1128/jvi.67.12.7556-7560.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Klessig D. F., Brough D. E., Cleghon V. Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell. Mol Cell Biol. 1984 Jul;4(7):1354–1362. doi: 10.1128/mcb.4.7.1354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kochanek S., Clemens P. R., Mitani K., Chen H. H., Chan S., Caskey C. T. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci U S A. 1996 Jun 11;93(12):5731–5736. doi: 10.1073/pnas.93.12.5731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Kolls J. K., Lei D., Odom G., Nelson S., Summer W. R., Gerber M. A., Shellito J. E. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther. 1996 Mar 1;7(4):489–497. doi: 10.1089/hum.1996.7.4-489. [DOI] [PubMed] [Google Scholar]
  32. Lei D., Lehmann M., Shellito J. E., Nelson S., Siegling A., Volk H. D., Kolls J. K. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats. Hum Gene Ther. 1996 Dec 1;7(18):2273–2279. doi: 10.1089/hum.1996.7.18-2273. [DOI] [PubMed] [Google Scholar]
  33. Lieber A., He C. Y., Kirillova I., Kay M. A. Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol. 1996 Dec;70(12):8944–8960. doi: 10.1128/jvi.70.12.8944-8960.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Marcellus R. C., Teodoro J. G., Wu T., Brough D. E., Ketner G., Shore G. C., Branton P. E. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. J Virol. 1996 Sep;70(9):6207–6215. doi: 10.1128/jvi.70.9.6207-6215.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Müller U., Kleinberger T., Shenk T. Adenovirus E4orf4 protein reduces phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of AP-1. J Virol. 1992 Oct;66(10):5867–5878. doi: 10.1128/jvi.66.10.5867-5878.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Nevels M., Rubenwolf S., Spruss T., Wolf H., Dobner T. The adenovirus E4orf6 protein can promote E1A/E1B-induced focus formation by interfering with p53 tumor suppressor function. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1206–1211. doi: 10.1073/pnas.94.4.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Nevins J. R. Mechanism of activation of early viral transcription by the adenovirus E1A gene product. Cell. 1981 Oct;26(2 Pt 2):213–220. doi: 10.1016/0092-8674(81)90304-4. [DOI] [PubMed] [Google Scholar]
  38. Nevins J. R. Utilization of cellular transcription factors for adenovirus-induced transcription. Virus Res. 1991 Jun;20(1):1–10. doi: 10.1016/0168-1702(91)90056-2. [DOI] [PubMed] [Google Scholar]
  39. Nordqvist K., Akusjärvi G. Adenovirus early region 4 stimulates mRNA accumulation via 5' introns. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9543–9547. doi: 10.1073/pnas.87.24.9543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nordqvist K., Ohman K., Akusjärvi G. Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs. Mol Cell Biol. 1994 Jan;14(1):437–445. doi: 10.1128/mcb.14.1.437. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Nordqvist K., Zerivitz K., Kreivi J. P., Ohman K., Akusjärvi G. Characterization of factors involved in regulated adenovirus-2 major late pre-mRNA splicing. Mol Biol Rep. 1990;14(2-3):203–204. doi: 10.1007/BF00360474. [DOI] [PubMed] [Google Scholar]
  42. Ohman K., Nordqvist K., Akusjärvi G. Two adenovirus proteins with redundant activities in virus growth facilitates tripartite leader mRNA accumulation. Virology. 1993 May;194(1):50–58. doi: 10.1006/viro.1993.1234. [DOI] [PubMed] [Google Scholar]
  43. Sandler A. B., Ketner G. Adenovirus early region 4 is essential for normal stability of late nuclear RNAs. J Virol. 1989 Feb;63(2):624–630. doi: 10.1128/jvi.63.2.624-630.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Sandler A. B., Ketner G. The metabolism of host RNAs in cells infected by an adenovirus E4 mutant. Virology. 1991 Mar;181(1):319–326. doi: 10.1016/0042-6822(91)90498-z. [DOI] [PubMed] [Google Scholar]
  45. Vilquin J. T., Guérette B., Kinoshita I., Roy B., Goulet M., Gravel C., Roy R., Tremblay J. P. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther. 1995 Nov;6(11):1391–1401. doi: 10.1089/hum.1995.6.11-1391. [DOI] [PubMed] [Google Scholar]
  46. Weiss R. S., Gold M. O., Vogel H., Javier R. T. Mutant adenovirus type 9 E4 ORF1 genes define three protein regions required for transformation of CREF cells. J Virol. 1997 Jun;71(6):4385–4394. doi: 10.1128/jvi.71.6.4385-4394.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Weiss R. S., Lee S. S., Prasad B. V., Javier R. T. Human adenovirus early region 4 open reading frame 1 genes encode growth-transforming proteins that may be distantly related to dUTP pyrophosphatase enzymes. J Virol. 1997 Mar;71(3):1857–1870. doi: 10.1128/jvi.71.3.1857-1870.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Weiss R. S., McArthur M. J., Javier R. T. Human adenovirus type 9 E4 open reading frame 1 encodes a cytoplasmic transforming protein capable of increasing the oncogenicity of CREF cells. J Virol. 1996 Feb;70(2):862–872. doi: 10.1128/jvi.70.2.862-872.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Wolff G., Worgall S., van Rooijen N., Song W. R., Harvey B. G., Crystal R. G. Enhancement of in vivo adenovirus-mediated gene transfer and expression by prior depletion of tissue macrophages in the target organ. J Virol. 1997 Jan;71(1):624–629. doi: 10.1128/jvi.71.1.624-629.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Worgall S., Wolff G., Falck-Pedersen E., Crystal R. G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997 Jan 1;8(1):37–44. doi: 10.1089/hum.1997.8.1-37. [DOI] [PubMed] [Google Scholar]
  51. Yang Y., Ertl H. C., Wilson J. M. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity. 1994 Aug;1(5):433–442. doi: 10.1016/1074-7613(94)90074-4. [DOI] [PubMed] [Google Scholar]
  52. Yang Y., Greenough K., Wilson J. M. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 1996 May;3(5):412–420. [PubMed] [Google Scholar]
  53. Yang Y., Li Q., Ertl H. C., Wilson J. M. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995 Apr;69(4):2004–2015. doi: 10.1128/jvi.69.4.2004-2015.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Yang Y., Nunes F. A., Berencsi K., Furth E. E., Gönczöl E., Wilson J. M. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4407–4411. doi: 10.1073/pnas.91.10.4407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Yang Y., Nunes F. A., Berencsi K., Gönczöl E., Engelhardt J. F., Wilson J. M. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet. 1994 Jul;7(3):362–369. doi: 10.1038/ng0794-362. [DOI] [PubMed] [Google Scholar]
  56. Yang Y., Su Q., Grewal I. S., Schilz R., Flavell R. A., Wilson J. M. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol. 1996 Sep;70(9):6370–6377. doi: 10.1128/jvi.70.9.6370-6377.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Yang Y., Trinchieri G., Wilson J. M. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med. 1995 Sep;1(9):890–893. doi: 10.1038/nm0995-890. [DOI] [PubMed] [Google Scholar]
  58. Yang Y., Wilson J. M. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996 Sep 27;273(5283):1862–1864. doi: 10.1126/science.273.5283.1862. [DOI] [PubMed] [Google Scholar]
  59. Yang Y., Wilson J. M. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol. 1995 Sep 1;155(5):2564–2570. [PubMed] [Google Scholar]
  60. Yang Y., Xiang Z., Ertl H. C., Wilson J. M. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7257–7261. doi: 10.1073/pnas.92.16.7257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Ye X., Robinson M. B., Batshaw M. L., Furth E. E., Smith I., Wilson J. M. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem. 1996 Feb 16;271(7):3639–3646. doi: 10.1074/jbc.271.7.3639. [DOI] [PubMed] [Google Scholar]
  62. Zsengeller Z. K., Wert S. E., Hull W. M., Hu X., Yei S., Trapnell B. C., Whitsett J. A. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther. 1995 Apr;6(4):457–467. doi: 10.1089/hum.1995.6.4-457. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES